KYTH Share Price

Open 74.99 Change Price %
High 74.99 1 Day -0.01 -0.01
Low 74.97 1 Week 0.00 0.00
Close 74.98 1 Month 0.00 0.00
Volume 1047607 1 Year 0.00 0.00
52 Week High 11.90
52 Week Low 0.00
KYTH Important Levels
Resistance 2 75.00
Resistance 1 74.99
Pivot 74.98
Support 1 74.97
Support 2 74.96
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ETRM 0.07 0.00%
AAPL 113.86 1.55%
AAPL 113.86 1.55%
More..
NASDAQ USA Top Gainers Stocks
HTCO 11.00 62.96%
LOCM 0.09 50.00%
OPXA 1.21 40.70%
QKLS 0.18 38.46%
ZAZA 0.08 33.33%
MOSY 0.46 31.43%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
PPHM 0.40 25.00%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
BGMD 0.05 -37.50%
More..

Kythera Biopharmaceuticals, Inc. (NASDAQ: KYTH)

KYTH Technical Analysis 5
As on 30th Sep 2015 KYTH Share Price closed @ 74.98 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 52.49 & Strong Buy for SHORT-TERM with Stoploss of 74.67 we also expect STOCK to react on Following IMPORTANT LEVELS.
KYTH Target for December
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
KYTH Other Details
Segment EQ
Market Capital 416392480.00
Sector Healthcare
Industry Drug Manufacturers - Major
Offical website http://www.kytherabiopharma.com
KYTH Address
KYTH
27200 West Agoura Road
Suite 200
Calabasas, CA 91301
United States
Phone: 818-587-4500
Fax: 818-587-4591
Interactive Technical Analysis Chart Kythera Biopharmaceuticals, Inc. ( KYTH NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Kythera Biopharmaceuticals, Inc.
KYTH Business Profile
KYTHERA Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of prescription products for the aesthetic medicine market. The Company�s initial focus is on the facial aesthetics market. The Company�s product candidate, ATX-101, is a injectable drug in Phase III clinical development for the reduction of submental fat, which commonly presents as an undesirable double chin. Based on clinical trials conducted, ATX-101 has exhibited results in the reduction of submental fat. ATX-101 contains a synthetic form of sodium deoxycholate. In the United States and Canada, the Company is conducting two pivotal Phase III trials of ATX-101 for the reduction of submental fat. The Company initiated this pivotal Phase III clinical program, with planned enrollment of 1,000 patients, in March 2012.